Avexis
Categories
Manufacturing
About Us
AveXis is a biotechnology company whose drug pipeline includes gene therapy preparations for rare neurological genetic disorders, the most advanced one being onasemnogene abeparvovec for spinal muscular atrophy, which was approved in May 2019. AveXis was acquired by Novartis in 2018